{"title":"Mpox: there is still risk of global outbreak.","authors":"Silvano Esposito, Chiara D'Amore, Flora Salzano, Pasquale Pagliano","doi":"10.1080/1120009X.2025.2476830","DOIUrl":null,"url":null,"abstract":"<p><p>Mpox is an emerging zoonosis that was first described in African animals, including monkeys, small rodents, and Gambian marsupial rats. It has since been identified as a sexually transmitted infection among humans. The disease is characterized by an incubation period ranging from 5 to 21 days, with the prodromal phase typically presenting nonspecific symptoms. The incubation period is followed by the development of the characteristic vesicular skin lesions that are the hallmarks of Mpox. Over the years, small outbreaks of Mpox have occurred regularly in Central and West Africa. In July 2022, the World Health Organization (WHO) declared the outbreak a Public Health Emergency of International Concern (PHEIC), due to the rapid spread of the virus in non-endemic countries. On May 11, 2023, WHO declared the end of the Mpox emergency, considering a significant decline in reported cases. As of October 2024, the true impact of this infection on international public health remains unclear.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-10"},"PeriodicalIF":1.9000,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Chemotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/1120009X.2025.2476830","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
Mpox is an emerging zoonosis that was first described in African animals, including monkeys, small rodents, and Gambian marsupial rats. It has since been identified as a sexually transmitted infection among humans. The disease is characterized by an incubation period ranging from 5 to 21 days, with the prodromal phase typically presenting nonspecific symptoms. The incubation period is followed by the development of the characteristic vesicular skin lesions that are the hallmarks of Mpox. Over the years, small outbreaks of Mpox have occurred regularly in Central and West Africa. In July 2022, the World Health Organization (WHO) declared the outbreak a Public Health Emergency of International Concern (PHEIC), due to the rapid spread of the virus in non-endemic countries. On May 11, 2023, WHO declared the end of the Mpox emergency, considering a significant decline in reported cases. As of October 2024, the true impact of this infection on international public health remains unclear.
期刊介绍：
The Journal of Chemotherapy is an international multidisciplinary journal committed to the rapid publication of high quality, peer-reviewed, original research on all aspects of antimicrobial and antitumor chemotherapy.
The Journal publishes original experimental and clinical research articles, state-of-the-art reviews, brief communications and letters on all aspects of chemotherapy, providing coverage of the pathogenesis, diagnosis, treatment, and control of infection, as well as the use of anticancer and immunomodulating drugs.
Specific areas of focus include, but are not limited to:
· Antibacterial, antiviral, antifungal, antiparasitic, and antiprotozoal agents;
· Anticancer classical and targeted chemotherapeutic agents, biological agents, hormonal drugs, immunomodulatory drugs, cell therapy and gene therapy;
· Pharmacokinetic and pharmacodynamic properties of antimicrobial and anticancer agents;
· The efficacy, safety and toxicology profiles of antimicrobial and anticancer drugs;
· Drug interactions in single or combined applications;
· Drug resistance to antimicrobial and anticancer drugs;
· Research and development of novel antimicrobial and anticancer drugs, including preclinical, translational and clinical research;
· Biomarkers of sensitivity and/or resistance for antimicrobial and anticancer drugs;
· Pharmacogenetics and pharmacogenomics;
· Precision medicine in infectious disease therapy and in cancer therapy;
· Pharmacoeconomics of antimicrobial and anticancer therapies and the implications to patients, health services, and the pharmaceutical industry.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
